Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease
AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.
How this was made
The 30-second read
Why it matters
The FDA clearance is a clear catalyst that could drive short‑term buying pressure and longer‑term revenue growth.
Market read
First‑time approval of a subcutaneous regimen for a major IBD drug, likely to move ABBV stock.
What to watch
Reimbursement policies for the new delivery method and potential competition from biosimilars could temper upside.
Background
AbbVie previously marketed SKYRIZI as an IV infusion; the new on-body injector offers at‑home administration.
Ticker impact
U.S. FDA approved AbbVie's subcutaneous induction regimen for SKYRIZI in Crohn's disease.
upward pressure as investors price in additional revenue from the SC formulation.
FDA approvals for new delivery methods are material catalysts for biotech stocks; the trial showed strong efficacy, suggesting rapid uptake.
Market effects
May lift other IBD therapeutic stocks as investors reassess the market size for subcutaneous biologics.
U.S. biotech sector could see modest gains on the day of the announcement.
Limited to markets with significant AbbVie exposure; no broad macro effect.
Counterpoint
If the SC formulation cannibalizes existing IV sales without expanding the patient base, the net revenue uplift could be muted.
Key entities
- companyAbbVie
U.S. pharmaceutical company developing SKYRIZI.
- regulatorFDA
U.S. Food and Drug Administration granting the approval.
